David A. Wohl, M.D.

Professor
University of North Carolina at Chapel Hill School of Medicine

Disclosure(s): Gilead: Advisor/Consultant, Grant/Research Support; Janssen: Advisor/Consultant; Lilly: Grant/Research Support; Merck: Grant/Research Support; ViiV: Advisor/Consultant, Grant/Research Support

Poster(s):

• 1063 - Female sex and SARS-CoV-2 Serostatus Predict Nasopharyngeal RNA Clearance during Early COVID-19
  Friday, October 21, 2022

  12:15 PM – 1:30 PM US ET

• 1277 - Provider Perspectives on Long-Acting Injectable Antiretroviral Therapy: A “Golden Ticket”?
  Friday, October 21, 2022

  12:15 PM – 1:30 PM US ET

• 2073 - Persistent HIV-1 Viremia Despite Intensive Antiviral Therapy Due to Non-responsive Clonal Viral Lineages
  Saturday, October 22, 2022

  12:15 PM – 1:30 PM US ET